Accepted for Publication: April 4, 2011.
Author Contributions: All authors had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Cruchaga, Kauwe, Holtzman, and Goate. Acquisition of data: Nowotny, Mayo, Fagan, and Morris. Analysis and interpretation of data: Cruchaga, Kauwe, Ridge, Bertelsen, Hinrichs, Fagan, Holtzman, and Goate. Drafting of the manuscript: Cruchaga, Nowotny, Kauwe, Holtzman, and Goate. Critical revision of the manuscript for important intellectual content: Cruchaga, Nowotny, Kauwe, Ridge, Mayo, Bertelsen, Hinrichs, Fagan, Holtzman, Morris, and Goate. Statistical analysis: Cruchaga, Kauwe, Bertelsen, and Hinrichs. Obtained funding: Holtzman, Morris, and Goate. Administrative, technical, and material support: Nowotny, Ridge, Mayo, Bertelsen, Fagan, Holtzman, Morris, and Goate. Study supervision: Holtzman, Morris, and Goate.
Financial Disclosure: Dr Morris has served as a consultant to or has received speaking honoraria from AstraZeneca AB, Bristol-Myers Squibb, Eisai Inc, Elan/Janssen Alzheimer Immunotherapy Program, Genentech Inc, Eli Lilly & Co, Merck & Co Inc, Novartis International AG, Otsuka Pharmaceuticals, Pfizer/Wyeth, and Schering-Plough. Dr Goate has served as a consultant to AstraZeneca; has provided expert testimony to Howrey & Associates; has speaking honoraria for AstraZeneca AB and Pfizer; and has received royalties from Taconic.
Funding/Support: This work was supported by grants AG16208, P01AG03991, P50AG05681, P01AG026276, AG23185, and AG05136 from the National Institutes of Health; the Barnes-Jewish Hospital Foundation; the Ford Foundation; and a fellowship from “Fundación Alfonso Martin Escudero” (Dr Cruchaga). Samples from the National Cell Repository for Alzheimer's Disease, which receives government support under a cooperative agreement grant (U24 AG21886) awarded by the NIA, were used in this study. Samples from the NIA-LOAD (National Institute on Aging Genetics Initiative for Late-Onset Alzheimer’s Disease) family study were collected under a cooperative agreement awarded by the NIA (U24 AG026395). Data collection and sharing for this project was funded by the ADNI (National Institutes of Health grant U01 AG024904). The ADNI is funded by the NIA, the National Institute of Biomedical Imaging and Bioengineering, and generous contributions from Abbott Laboratories, AstraZeneca AB, Bayer Schering Pharma AG, Bristol-Myers Squibb, Eisai Global Clinical Development, Elan Corp, Genentech, GE Healthcare, GlaxoSmithKline, Innogenetics, Johnson & Johnson, Eli Lilly & Co, Medpace Inc, Merck & Co Inc, Novartis International AG, Pfizer Inc, F. Hoffman-La Roche, Schering-Plough, and Synarc Inc and from the nonprofit partners the Alzheimer's Association and the Alzheimer's Drug Discovery Foundation, with participation from the US Food and Drug Administration. Private sector contributions to the ADNI are facilitated by the Foundation for the National Institutes of Health (http://www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. The ADNI data are disseminated by the Laboratory for NeuroImaging at the University of California, Los Angeles. This research was also supported by grants P30 AG010129 and K01 AG030514 from the National Institutes of Health and by the Dana Foundation.
Role of the Sponsor: The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
A complete list of ADNI investigators can be found at http://adni.loni.ucla.edu/wp-content/uploads/how_to_apply/ADNI_Authorship_List.pdf.
Disclaimer: Data used in the preparation of this article were obtained from the ADNI database (http://www.loni.ucla.edu/ADNI). As such, the investigators in the ADNI contributed to the design and implementation of the ADNI and provided data but did not participate in analysis or writing of this report.
Previous Presentation: This study is presented in part at the International Conference on Alzheimer Disease; July 16-21, 2011; Paris, France.
Online-Only Materials: The supplemental figures and table can be found at http://neuroscienceresearch.wustl.edu/Pages/cruchaga2011.aspx.
Additional Contributions: We thank the contributors, including the AD centers, who collected the samples used in this study; the patients and their families, whose help and participation made this work possible; the Clinical Core of the Knight ADRC for clinical and cognitive assessments of the participants; the Genetics Core of the Knight ADRC for APOE genotypes; and the Biomarker Core of the Adult Children Study for the CSF collection and assays.